aBLA Filing Intelligence & Biosimilar Opportunity

Unloxcyt

Cosibelimab-Ipdl

Anticancer

Injection

Unloxcyt is an IV anti–PD-L1 antibody for adults with advanced or metastatic cutaneous squamous cell carcinoma who are not surgical or radiation candidates. It helps the immune system fight cancer by blocking PD-L1, with a documented response in nearly half of patients.

Approval Date

13-Dec-24

Data Exclusivity Expiry

13-Dec-28

Market Exclusivity Expiry

13-Dec-36

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

117

2028

171

2029

242

2030

310

2031

385

2032

464

Molecule profile

Details & specifications

Molecule

Cosibelimab-Ipdl

Innovator

CHECKPOINT THERAPEUTICS INC

Dosage Form

Injection

Strength

300 mg/5 mL (60 mg/mL)

Therapeutic Category

Anticancer

Usage

To treat cutaneous squamous cell carcinoma

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets